Tags Archive Navigation
icon
-
Media ReleaseNew Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept
-
Media ReleaseNovartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
-
Media ReleaseNovartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
-
Media ReleaseNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
-
Media ReleaseNovartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
-
Media ReleaseFDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Media ReleaseNovartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
-
Media ReleaseNovartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
-
Media ReleaseNovartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media ReleaseNovartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
-
StoryInspiring a daughter to make her own path
-
StoryReimagining asthma care: how data and digital could bring asthma management goals within reach
Pagination
- ‹ Previous page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- › Next page